134 related articles for article (PubMed ID: 11061618)
1. Hepatocellular carcinoma after long-term tamoxifen therapy.
Moffat DF; Oien KA; Dickson J; Habeshaw T; McLellan DR
Ann Oncol; 2000 Sep; 11(9):1195-6. PubMed ID: 11061618
[TBL] [Abstract][Full Text] [Related]
2. The association between tamoxifen and the development of hepatocellular carcinoma: case report and literature review.
Law CH; Tandan VR
Can J Surg; 1999 Jun; 42(3):211-4. PubMed ID: 10372018
[TBL] [Abstract][Full Text] [Related]
3. Axillary lymph node metastases as the sole clinical site of occult breast carcinoma.
Dragoumis DM; Tsiftsoglou AP; Sikou AD; Assimaki AS
J Coll Physicians Surg Pak; 2008 Aug; 18(8):517-9. PubMed ID: 18798593
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen and secondary tumours. An update.
Wilking N; Isaksson E; von Schoultz E
Drug Saf; 1997 Feb; 16(2):104-17. PubMed ID: 9067122
[TBL] [Abstract][Full Text] [Related]
5. [A case regarded as an occult breast cancer treated without mastectomy].
Kawashima T; Miyazawa Y; Sakata H; Matsubara H; Ryu M; Ochiai T
Gan To Kagaku Ryoho; 2005 Jun; 32(6):825-8. PubMed ID: 15984524
[TBL] [Abstract][Full Text] [Related]
6. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
7. Audit of a conservative management policy of the axilla in elderly patients with operable breast cancer.
al-Hilaly M; Willsher PC; Robertson JF; Blamey RW
Eur J Surg Oncol; 1997 Aug; 23(4):339-40. PubMed ID: 9315064
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence.
Fisher BJ; Perera FE; Cooke AL; Opeitum A; Stitt L
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):117-23. PubMed ID: 9747828
[TBL] [Abstract][Full Text] [Related]
9. A decision analysis of the effect of avoiding axillary lymph node dissection in low risk women with invasive breast carcinoma.
Jackson JS; Olivotto IA; Wai M D E; Grau C; Mates D; Ragaz J
Cancer; 2000 Apr; 88(8):1852-62. PubMed ID: 10760762
[TBL] [Abstract][Full Text] [Related]
10. Administration of tamoxifen in the perioperative period to patients with breast carcinoma prolongs axillary fluid drainage.
Kelessis NG; Vassilopoulos PP; Galanopoulou AV; Nessiotis AG; Stravolemos CM
Anticancer Res; 2000; 20(2B):1245-8. PubMed ID: 10810428
[TBL] [Abstract][Full Text] [Related]
11. Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla?
Martelli G; Miceli R; De Palo G; Coradini D; Salvadori B; Zucali R; Galante E; Marubini E
Cancer; 2003 Mar; 97(5):1156-63. PubMed ID: 12599220
[TBL] [Abstract][Full Text] [Related]
12. THE SIGNIFICANCE OF REGIONAL LUMPH NODE METASTASES IN BREAST CARCINOMA.
DEVITT JE
Can Med Assoc J; 1965 Aug; 93(7):289-93. PubMed ID: 14319790
[TBL] [Abstract][Full Text] [Related]
13. The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977.
Mühlemann K; Cook LS; Weiss NS
Breast Cancer Res Treat; 1994; 30(2):201-4. PubMed ID: 7949218
[TBL] [Abstract][Full Text] [Related]
14. Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes.
Hoebers FJ; Borger JH; Hart AA; Peterse JL; Th EJ; Lebesque JV
Cancer; 2000 Apr; 88(7):1633-42. PubMed ID: 10738222
[TBL] [Abstract][Full Text] [Related]
15. Segmental mastectomy and tamoxifen alone provide adequate locoregional control of breast cancer in elderly women.
Yeh S; Tan LR; O'Connell TX
Am Surg; 1997 Oct; 63(10):854-7. PubMed ID: 9322656
[TBL] [Abstract][Full Text] [Related]
16. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
[TBL] [Abstract][Full Text] [Related]
17. Scientific review of tamoxifen. Overview from a medical oncologist.
Carlson RW
Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-151-S1-7. PubMed ID: 9045312
[TBL] [Abstract][Full Text] [Related]
18. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
Tormey DC; Gray R; Falkson HC
J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen-induced QT interval prolongation.
Slovacek L; Ansorgova V; Macingova Z; Haman L; Petera J
J Clin Pharm Ther; 2008 Aug; 33(4):453-5. PubMed ID: 18613864
[TBL] [Abstract][Full Text] [Related]
20. [A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
Katsuta E; Ohkubo T; Someno Y; Saguchi M; Aoyagi H; Takahata T; Hasegawa K; Hamada S; Kaneko J; Maejima S
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2760-2. PubMed ID: 21224704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
